Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit Insights From the DANISH Trial

被引:43
|
作者
Kristensen, Soren Lund [1 ,2 ]
Levy, Wayne C. [3 ]
Shadman, Ramin [4 ]
Nielsen, Jens C. [5 ]
Haarbo, Jens [6 ]
Videbaek, Lars [7 ]
Bruun, Niels E. [8 ,9 ,10 ]
Eiskjaer, Hans [5 ]
Wiggers, Henrik [5 ]
Brandes, Axel [7 ]
Thogersen, Anna Margrethe [11 ]
Hassager, Christian [1 ,12 ]
Svendsen, Jesper H. [1 ,12 ]
Hofsten, Dan E. [1 ]
Torp-Pedersen, Christian [11 ]
Pehrson, Steen [1 ]
Signorovitch, James [13 ]
Kober, Lars [1 ,12 ]
Thune, Jens Jakob [2 ,12 ]
机构
[1] Copenhagen Univ Hosp, Dept Cardiol, Rigshosp, Copenhagen, Denmark
[2] Bispebjerg Hosp, Dept Cardiol, Copenhagen, Denmark
[3] Univ Washington, Seattle, WA 98195 USA
[4] Southern Calif Permanente Med Grp, Los Angeles, CA USA
[5] Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark
[6] Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark
[7] Odense Univ Hosp, Dept Cardiol, Odense, Denmark
[8] Zealand Univ Hosp, Dept Cardiol, Roskilde, Denmark
[9] Clin Inst, Copenhagen, Denmark
[10] Aalborg Univ, Aalborg, Denmark
[11] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark
[12] Univ Copenhagen, Dept Clin Med, Fac Hlth & Med Sci, Copenhagen, Denmark
[13] Anal Grp, Boston, MA USA
关键词
implantable cardioverter-defibrillator; nonischemic cardiomyopathy; risk prediction; SEATTLE HEART-FAILURE; SUDDEN CARDIAC DEATH; PRIMARY PREVENTION; DILATED CARDIOMYOPATHY; PROPORTIONAL RISK; AMIODARONE; SURVIVAL; THERAPY;
D O I
10.1016/j.jchf.2019.03.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study aims to identify patients with nonischemic heart failure who are more likely to benefit from implantable cardioverter-defibrillator (ICD) implantation by use of established risk prediction models. BACKGROUND It has been debated whether an ICD for primary prevention reduces mortality in patients with nonischemic heart failure. METHODS The Seattle Heart Failure Model (SHFM) predicts all-cause mortality whereas the Seattle Proportional Risk Model (SPRM) predicts the proportion of sudden cardiac death (SCD) versus nonsudden death, with a higher score indicating a greater proportion of SCD. We report the effect of ICD implantation on all-cause mortality and SCD, according to median SPRM and SHFM scores in all 1,116 patients enrolled in the DANISH (Danish study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on mortality) trial. RESULTS Among patients with an SPRM score above the median (n = 558), ICD implantation reduced all-cause mortality (hazard ratio [HR]: 0.63; 95% confidence interval [CI]: 0.43 to 0.94), whereas patients with lower SPRM scores (n = 558) had no effect (HR: 1.08; 95% CI: 0.78 to 1.49, p for interaction = 0.04). The corresponding numbers for SHFM score above and below the median were HR: 0.84; 95% CI: 0.62 to 1.13 and HR: 0.82; 95% CI: 0.53 to 1.28, respectively (p for interaction = 0.980). In 177 patients with upper SPRM/upper SHFM, ICD implantation reduced all-cause mortality (HR: 0.45; 95% CI: 0.25 to 0.80) when compared to 381 patients with lower SPRM/upper SHFM (HR: 1.09; 95% CI: 0.76 to 1.55) (p for interaction < 0.001). CONCLUSIONS Nonischemic heart failure patients with high predicted relative likelihood of SCD, as estimated by higher SPRMscore, seemed to benefit from ICD implantation. (C) 2019 by the American College of Cardiology Foundation.
引用
收藏
页码:717 / 724
页数:8
相关论文
共 50 条
  • [1] Predicting benefit for implantable cardioverter-defibrillator use
    Soliman, Elsayed Z.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (03): : 286 - 287
  • [2] Implantable Cardioverter-Defibrillator Registry Risk Score Models for Acute Procedural Complications or Death After Implantable Cardioverter-Defibrillator Implantation
    Haines, David E.
    Wang, Yongfei
    Curtis, Jeptha
    CIRCULATION, 2011, 123 (19) : 2069 - 2076
  • [3] The implantable cardioverter-defibrillator
    Raj, SR
    Sheldon, RS
    PROGRESS IN CARDIOVASCULAR DISEASES, 2001, 44 (03) : 169 - 194
  • [4] The implantable cardioverter-defibrillator
    Greene, HL
    CLINICAL CARDIOLOGY, 2000, 23 (05) : 315 - 326
  • [5] The implantable cardioverter-defibrillator
    Groh, WJ
    Foreman, LD
    Zipes, DP
    AMERICAN FAMILY PHYSICIAN, 1998, 57 (02) : 310 - 312
  • [6] Predicting benefit for implantable cardioverter-defibrillator use - Reply
    Redberg, Rita F.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (03): : 287 - 287
  • [7] Prediction of benefits from prophylactic implantable cardioverter-defibrillator therapy
    Huikuri, Heikki V.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 243 : 274 - 275
  • [8] Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator
    Klein, Helmut U.
    Goldenberg, Ilan
    Moss, Arthur J.
    EUROPEAN HEART JOURNAL, 2013, 34 (29) : 2230 - 2242
  • [9] Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy - The Canadian implantable defibrillator study
    Sheldon, R
    Connolly, S
    Krahn, A
    Roberts, R
    Gent, M
    Gardner, M
    CIRCULATION, 2000, 101 (14) : 1660 - 1664
  • [10] Implantable cardioverter-defibrillator therapy of short QT syndrome is associated with an inherent risk of inappropiate implantable cardioverter-defibrillator discharges
    Schimpf, R
    Wolpert, C
    Bianchi, F
    Giustetto, C
    Bauersfeld, U
    Gaita, F
    Borggrefe, M
    EUROPEAN HEART JOURNAL, 2004, 25 : 28 - 28